INSM Insmed, Inc.

18.03
+0.08  (0%)
Previous Close 17.95
Open 17.99
Price To book 9.16
Market Cap 1.12B
Shares 62,090,000
Volume 522,409
Short Ratio 11.55
Av. Daily Volume 316,303

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 to be initiated 2H 2017.
INS1007
Bronchiectasis
Phase 2 ready.
INS1009
Pulmonary arterial hypertension (PAH)
Phase 2 trial to be initiated in 2017.
AZD7986
Non-cystic fibrosis bronchiectasis
Phase 3 Euro data released 1 July 2013. Met endpoint but slighly inferior data to competition
ARIKAYCE
Cystic fibrosis
Phase 3 data due September 2017 timeframe plus or minus a month.
ARIKAYCE
Non-tuberculous Mycobacterial Lung Disease